Update on the bifurcated EXCLUDER endoprosthesis: Phase I results  by Matsumura, Jon S et al.
S150
enrolled at three centers from January 6, 1998, through
October 10, 1998, after the institutional review
board–approved informed consent was obtained. Patient
follow-up was scheduled at discharge, 3 months, 6 months,
12 months, and annually and included clinical and com-
puted tomography examinations. These data summarize
information provided to the sponsor by participating inves-
tigators as of September 17, 1999. The authors were able
to personally review case report forms and primary source
documents. The sponsor reviewed the paper only for pro-
prietary information and technical accuracy; the authors
retained final review authority.
The EXCLUDER is a modular bifurcated endovascular
system for the treatment of abdominal aortic aneurysms (Fig
1). The endoprosthesis skeleton is made of thermosensitive
nitinol, spans the length of each component, and provides
radial strength to prevent kinking and to assist sealing and
fixation to the arterial wall. At the craniad end of the trunk-
ipsilateral leg endoprostheses (trunk-ipsi) component, there
are eight pairs of anchors to improve fixation to the
infrarenal aortic neck. The skeleton pattern is designed to
accommodate longitudinal shortening and a large degree of
tortuosity. Polytetrafluoroethylene (PTFE) graft material is
attached to the nitinol with polyethylene tape so that no
sutures or suture holes are present in the graft material that
lines the entire luminal surface. PTFE technology permits
the manufacture of endoprostheses in tapered configurations
that allow the design of an endoprosthesis system in which
components are universally compatible, thus expanding the
available configurational options. Specifically, the trunk-ipsi
components in the phase I study are available in three aortic
diameters, two lengths, and two ipsilateral iliac diameters.
Each trunk-ipsi has a contralateral leg hole, which matches
every available contralateral leg endoprosthesis (contra leg),
such that combinations of two different iliac lengths and dif-
ferent iliac diameters are possible with any aortic diameter.
This is in contrast with current standard aortic grafts, which
come with equal iliac diameters, roughly one half of the size
of the aortic diameter. Tapered grafts also allow long and
wide diameter junctions between components that may
reduce late dislocation and improve patency.
Endovascular repair has become a viable alternative for
patients with abdominal aortic aneurysms, provided that
the infrarenal anatomy is suitable. Many patients, however,
have anatomy that is not amenable to treatment with cur-
rently approved endografts, including severe tortuosity,
calcification, and stenosis of iliac arteries. Some devices
lack sufficient graft support in the midbody and limbs to
resist kinking, which may contribute to reduced limb flow;
other devices use a thinner polyester graft material that
may permit transgraft perfusion of the aneurysm.1,2 Next
generation endoprostheses must be designed to overcome
these and other anticipated difficulties. An ideal endograft
would be uncomplicated to use, accommodate difficult
anatomy, be impermeable to blood, and require a mini-
mum of adjunctive or subsequent procedures. This study
describes the phase I initial experience with a still-investi-
gational device that was engineered to provide durable
exclusion of an infrarenal aortic aneurysm, have excellent
limb patency, and be simple to place in patients with chal-
lenging iliac anatomy.
METHODS
This report summarizes the results of a phase I, Food
and Drug Administration–approved, feasibility study of the
bifurcated EXCLUDER endoprosthesis (EXCLUDER;
W.L. Gore and Associates, Flagstaff, Ariz). Patients were
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Many devices are being investigated for treatment of infrarenal abdominal aortic aneurysms. This report describes the
particular characteristics of a next generation modular endograft and the Phase I results in 29 patients. Larger compar-
ative studies are in progress to assess the safety and efficacy of this new design. (J Vasc Surg 2001;33:S150-3.)
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A prominent feature of the deployment system is the
lack of a rigid delivery system that may distort the arterial
anatomy and increase the risk of arterial injury during
insertion. Instead, the endoprosthesis is constrained by a
flexible PTFE sleeve that is released by pulling on a
deployment cord. Rapid placement occurs with minimal
foreshortening. Flexibility, pushability, and torque respon-
siveness facilitate positioning through tortuous and calci-
fied iliac arteries. An 18F (inner diameter) sheath is used
to introduce the trunk-ipsi prosthesis; the contra leg is
inserted through a 12F sheath. Radiopaque markers are
attached to the proximal and distal ends of each compo-
nent and the trunk-ipsi flow divider so that recommended
overlap zones are conspicuous fluoroscopically. An addi-
tional longer marker designates the contralateral side of
the undeployed trunk-ipsi for rotational orientation, and a
radiopaque ring aids visualization of the contralateral leg
hole during retrograde cannulation.
Twenty-nine subjects were enrolled (27 male [93%]
and two female [7%]; mean age, 76 years; range, 59-91
years). The mean maximum aneurysm diameter was 5.7
cm (range, 4.5-9.0 cm), and the aneurysm classification
by The Society for Vascular Surgery/International
Society for Cardiovascular Surgery reporting standards
was I in 25 subjects (86%), II in three subjects (10%), and
III in one subject (4%).3 The New York Heart
Association classification was I in 22 subjects (76%), II in
five subjects (17%), and III in two subjects (7%). The
American Society of Anesthesioloists classification was I
in three subjects (10%), II in seven subjects (24%), III in
14 subjects (48%), and IV in five subjects (17%). Other
specific pretreatment conditions are listed in Table I.
Preoperative measurement of the patient’s anatomy and
selection of an appropriate patient and combination of
components to be available on site are critical compo-
nents of endovascular treatment of aortic aneurysms. In
this study, thin-slice computed tomography and marker
catheter angiography were routinely used. Each subject
underwent trunk-ipsi endoprosthesis and one contra leg
implantation. Three patients underwent an additional
contra leg implantation to extend the length and improve
the seal in the iliac artery.
Table I. Severity rating of subject comorbidities
Severity* (n; %) 
Condition 0 1 2 3
Hypertension 8 (28) 12 (41) 5 (17) 4 (14)
Renal status 25 (86) 3 (10) 1 (4) 0 (0)
Hyperlipidemia 18 (64) 5 (18) 1 (4) 4 (14)
Diabetes 23 (82) 0 (0) 5 (18) 0 (0)
Tobacco use 16 (57) 5 (18) 4 (14) 3 (11)
Cardiac status 14 (50) 9 (32) 5 (18) 0 (0)
Carotid disease 23 (82) 5 (18) 0 (0) 0 (0)
Pulmonary status 20 (77) 3 (12) 2 (8) 1 (4)
*n = 29; All risk factors were not reported for some subjects.
Table II. Adverse events
Anticipated Treatment through Discharge through Month 3 through Month 6 through
adverse event discharge (n = 29) month 3 (n = 29) month 6 (n = 27) month 12 (n = 22)
Death — — — —
Myocardial infarction — — — —
Arrhythmia — — 1 —
Angina — 1 — —
Stroke — — — —
Transient ischemic attack — — — 1
Graft infection — 1 — —
Renal thrombosis — 1 — —
Acute renal tubular necrosis 1 — — —
Procedural blood loss 1 — — —
Hematoma 1 — — —
Seroma/lymphocele 1 3 — —
Arteriovenous fistula 1 — — —
Iliac dissection 1 1 — —
Deep venous thrombosis — 1 — —
Buttock/thigh claudication 1 2 — —
Testicular pain — — 1 —
Contrast reaction — — 1 —
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RESULTS
All endoprostheses were successfully deployed, and
there were no immediate conversions. No deaths have
occurred. Thirteen patients had 19 complications (Table
II). As adverse events are the primary focus of phase I stud-
ies, they will be presented and discussed in detail.
Individual complications. Many complications are
related to the procedure and reflect the significant risks
associated with vascular procedures. A 73-year-old man
underwent intentional hypogastric artery embolization
and experienced ipsilateral buttock and thigh claudication.
He also had an iliac artery dissection. Both resolved with-
out treatment by 6 months. A 68-year-old man underwent
a more extensive procedure that included simultaneous
balloon angioplasty of the iliac arteries and had a 3-unit
procedural blood loss that was treated with cell-saver
transfusion and 4 L of crystalloid. An 82-year-old man
underwent an iliac artery dissection that resolved without
treatment by 3 months. He also experienced a reaction to
contrast media that was administered intravenously at the
6 months visit and is now followed with magnetic reso-
nance imaging. A 59-year-old man had an ipsilateral groin
wound lymph leak that was present at 6 weeks and
resolved by 3 months. A 79-year-old man had acute tubu-
lar necrosis that resolved after no further contrast media
was given. At 3 months, he complained of bilateral thigh
claudication, which was observed. At 4 months, he had
ventricular tachycardia treated with an implantable defib-
rillator.
Some procedure-related complications are directly
related to percutaneous access of the contralateral leg. A
70-year-old man had an arteriovenous fistula noted in the
groin before discharge, which resolved by 3 months. A 63-
year-old man had a groin hematoma that resolved by 3
months, at which time he also reported an interval episode
of angina that was referred to his cardiologist. An 82-year-
old man had a groin seroma at 1 month that was treated
with aspiration. A 91-year-old man had a lymphocele
noted at 6 weeks, which was observed.
Other complications are possibly related to the proce-
dure but also may be related to patient comorbidities. An
87-year-old man had testicular pain at the 6-month visit that
was observed. An 88-year-old man experienced calf claudi-
cation that was caused by a superficial femoral artery steno-
sis at his 3-month visit and a transient ischemic attack at 11
months. He was treated with medication. A 73-year-old man
had a femoral deep venous thrombosis at 3 months, which
was asymptomatic but still present at 12 months.
The most interesting and severe complication
occurred in a 72-year-old man who underwent treatment
in an endovascular suite. He was discharged on postoper-
ative day 3. One month later, he returned with fever and
back pain; a computed tomography scan showed periaor-
tic inflammation without evidence of rupture. Blood cul-
tures were positive for Staphylococcus aureus, and aspiration
of perigraft fluid also showed S aureus. The patient was
treated with antibiotics, extra-anatomic bypass with axillo-
bifemoral bypass grafting, and staged explantation of the
endoprosthesis. During the explantation, an aortoduodenal
fistula was found caudal to the proximal neck and repaired.
Additionally, a left renal artery embolus was found and
removed. The patient recovered and is doing well. A review
of central quality control and sterilization procedures
revealed no evidence of contamination, and the bacterio-
logic evidence suggests that procedural skin contamination
was more likely than a primary aortoenteric fistula.
Endoleaks. The investigator-reported endoleak rate
at discharge is 39% (n = 28 subjects), at 3 months is 23%
(n = 26 subjects), at 6 months is 24% (n = 25 subjects),
and at 12 months is 16% (n = 19 subjects). Most patients
(60%) with endoleaks had only type II or branch flow.
Three patients had a proximal attachment site endoleak,
two of which resolved, but one of which persists in a
patient with a short and angled proximal neck. The
Fig 1. Photograph of a bifurcated excluder endoprosthesis shows
the exoskeleton that extends throughout the graft and shows the
flexibility of the deployment catheter (black arrow). The black
arrowhead indicates the proximal anchors.
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aneurysm in this patient has not increased in size, and she
is not a candidate for treatment with an aortic cuff because
of severe angulation. In retrospect, she should not have
been treated with the endoprosthesis. She has refused con-
version to open operation. Two patients had endoleaks of
unknown source, one of whom is the only patient who
had aneurysm enlargement of over 5 mm. Both indeter-
minate endoleaks have resolved, and there has been no
further aneurysm enlargement. One patient had an
endoleak from a distal limb attachment site at discharge,
with persistence at 3 months and at 6 months.
Aside from the one patient with abdominal aortic
aneurysm expansion, there has been no other expansion or
aneurysm rupture, limb occlusion, or migration in any
patients in this relatively short follow-up period (mean, 11
months; maximum, 20 months).
DISCUSSION
Phase I trials are feasibility studies and, by design, are
relatively small and focused on safety evaluation. The inci-
dence and severity of adverse events in this study are com-
parable to overall published data for patients who undergo
open and endovascular repair and justifies proceeding with
larger trials.2,4,5 Within this small sample size and short
follow-up period, no deaths or ruptures have occurred. It
is certain that with greater numbers of implantations and
longer surveillance periods that deaths will occur and a
high index of sensitivity to ruptures must be maintained.
At the same time, it is encouraging that this advanced
device design is not associated with limb occlusion or an
inability to complete the procedure and that there has
been no migration detected.
Complications, especially endoleaks, are generally
under reported compared with core laboratory diagnoses;
the endoleak rate may be found to be greater with central
independent assessment, which is a feature of the phase II
trial that is now being completed. It is interesting that the
endoleak rate in this phase I study is remarkably similar to
that reported with other devices, both at discharge and the
12-month time point.6 The usual predominance of type II
endoleaks in these studies and the anatomic nature of
branch reperfusion suggest that this type of endoleak will
be a universal phenomena until newer techniques are
developed. Long-term research will reveal the clinical sig-
nificance of branch endoleaks after endovascular repair.
Infection of an endoprosthesis is surprisingly uncom-
mon, despite initial concerns with placing a prosthetic graft
in proximity to an aneurysm thrombus that is known to
harbor bacterial pathogens. Early encounters with postim-
plantation syndrome and its accompanying fevers had gen-
erated significant anxiety and testing. Postimplantation
syndrome has been shown to be associated with fever and
serologic abnormalities but with no identifiable bacterial
infection.7 With several years of experience, many physi-
cians are becoming complacent in this regard; this endo-
graft infection should reemphasize the importance of
reducing this risk. Aortic prosthetic graft infection remains
a dreaded life-threatening complication that often requires
multiple corrective procedures. Treatment was based on
established vascular surgery principles and was successful
in this case. However, it is still essential that all reasonable
preventative measures be used; this trial group has used
routine antibiotic prophylaxis and stressed adherence to
strict aseptic technique. Perhaps it is more important that
handling be minimized with this endoprosthesis than with
other endografts in which direct contact is automatically
limited by a jacket, removable capsule, or cartridge. Many
centers choose to use angiographic suites for implantation
procedures because of the availability of excellent imaging
capabilities, but standard infection control measures must
be used in any location in which aortic grafts are placed.
Larger studies will be needed to determine whether there
is any relative impact of procedure location because of
advanced imaging or infection risk on clinical outcomes.
SUMMARY
The bifurcated EXCLUDER endoprosthesis is an
investigational device, and phase I data demonstrate feasi-
bility in the treatment of abdominal aortic aneurysms.
Phase II multicenter clinical trials in the United States are
under way to better evaluate safety and effectiveness. The
phase II study of this device has completed enrollment and
entered the important follow-up stage. These investiga-
tions will measure the value of several innovative engi-
neering features.
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